Cancer screening aims to identify cancer before indications appear. It includes urine tests, DNA tests, blood tests, medical imaging etc. Some types of screening include biopsy tests, Human Chorionic Gonadotropin (HCG) Test, laboratory tests, tumor cancer diagnostics, imaging procedures, and genomic tests. Genomic tests involve prenatal testing, diagnostic testing, carrier testing, and neonatal testing. In addition, some treatments included radiation therapy, hormonal therapy, immunotherapy, chemotherapy, and targeted therapy. Hormonal therapy includes leuprolide and goserelin. Immunotherapy includes paclitaxel and carbonating. Chemotherapy includes paclitaxel, cisplatin, docetaxel, carboplatin, and others. In addition, targeted therapy includes olaparib and bevacizumab.
According to study, “MEA Cancer Screening Market (2018-2023)” some of the major companies that are currently working in the MEA cancer screening market are Thermo Fisher Scientific, GE Healthcare, Quest Diagnostics Inc., Illumina Inc.,ELITech Group, Genentech Inc., Abbott Laboratories, Siemens Healthineers, Eli Lilly and Company, Roche Diagnostics Corp., Abbott Molecular Inc., Janssen Pharmaceuticals, Inc., AutoGenomics Inc., Applied Biosystems Inc., GlaxoSmithKline Plc., Astra Zeneca BoehringerIngelheim, PerkinElmer Inc., Bristol Myers Squibb Company, F. Hoffman-La Roche Ltd, Transgenomic Inc., BioRad Laboratories, Celera Group Inc., RocheMolecular Diagnostics Inc. These key players are involved in collaboration with the aim to provide superior technology for the diagnosis of cancer.
Based on the usage, the MEA cancer screening market is segmented into colorectal cancer, melanoma, skin cancer, cervical cancer, stomach cancer, blood cancer, breast cancer, pancreatic cancer, and ovarian cancer. Based on technologies, the market is defined by tests such as platform-based diagnostics, instrument-based and tumor biomarkers test. Based on the therapeutic, the market is segmented into fluorouracil, erlotinib hydrochloride (Tarceva), paclitaxel-albumin (Abraxane), gemcitabine hydrochloride, everolimus (affinity), mitomycin C, irinotecan hydrochloride, sunitinib malate (stent) and others. Based on the end user, this market is classified as hospital-associated labs, cancer research institutes, and diagnostic laboratories etc.
The National Organized Cervical Cancer Screening (NOCCS) is a government program in the Middle East region, for the cancer screening, which is diagnosing late and is associated with a high mortality rate. Some of the obstacles of NOCCS are lack of political understanding to maintain public health programs & providing the necessary resources and lack of knowledge of the disease, socio-religious & cultural barriers, and geographic &cost-effective difficulties in accessing medical services. Most countries of the region practice more or less limited opportunistic, screening tests, cytology-based which frequently lack quality assurance & follow-up care. In addition, National Cancer Control Plan (NCCP) is responsible for implementing screening programming organizations mainly for cervical cancer detection. The Middle East & Africa cancer screening market is driven by the aging population, rise in the prevalence of target disorders, greater use of combination therapies, increasing population of aged women, increasing venture in biotechnology & pharmaceutical industries for R&D, increasing support from the government in the form of performance-based reimbursements & awareness campaigns and the presence of favorable government initiatives. However, an imbalance in its socio-economic &political scenario, patent expiry of key drugs, the high cost of diagnostic imaging systems, drug toxicity & side effects, stringent regularly guidelines, lack of accurate diagnosis and high capital investments are the main hinder factors for this market.
The Middle East and Africa cancer screening market are rising at a very slow rate owing to the limited availability of medical facilities. The Saudi Arabia, UAE (United Arab Emirates) and Kuwait are anticipated to drive the MEA market and the African region is predictable to witness a moderate growth. It is expected that the MEA market will be reached US$50.6 billion, at a compound CAGR of 11.5%, by 2023.
To know more, click on the link below:-
https://www.kenresearch.com/healthcare/medical-devices/mea-cancer-screening-2018-2023/172428-91.html
Related Reports:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
No comments:
Post a Comment